SCHEMBL5916501

SCHEMBL5916501

O=c1c2cc([N+](=O)[O-])ccc2[se]n1-c1nccs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ LMNA P02545 3/20 0.39
▸ MAPT P10636 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ G6PD P11413 2/20 0.39
▸ TLR9 Q9NR96 1/20 0.39
▸ KAT2B Q92831 4/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ PARP1 P09874 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ PHOSPHO1 Q8TCT1 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ MPI P34949 1/20 0.36
▸ EP300 Q09472 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10501717 0.88 LMNA (0.35) L3MBTL1LMNAMAPTPOLBHTT
SCHEMBL10748866 0.81 L3MBTL1 (0.43) L3MBTL1LMNAMAPTPOLBHTT
SCHEMBL5916810 0.79 METAP2 (0.40) LMNAMAPTPOLBHTTNPSR1
SCHEMBL5916533 0.78 KMT2A (0.45) L3MBTL1LMNAMAPTPOLBG6PD
SCHEMBL10502494 0.76 TXNRD1 (0.52) POLBKAT2BMEN1KMT2AKDM4E
SCHEMBL10502469 0.76 METAP2 (0.59) LMNAMAPTPOLBHTTNPSR1
SCHEMBL5916638 0.76 METAP2 (0.54) LMNAMAPTPOLBHTTNPSR1
SCHEMBL10501567 0.73 ALDH1A1 (0.38) L3MBTL1MAPTPOLBNPSR1G6PD
SCHEMBL18770213 0.72 ALDH1A1 (0.41) L3MBTL1MAPTG6PDTLR9PHOSPHO1
SCHEMBL5916770 0.71 METAP2 (0.40) MAPTG6PDKAT2BKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US claimed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP claimed
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2006-06-22 — — US disclosed
EP-1541145-A1 THE USE OF BENZISOSELENAZOLONE COMPOUNDS AGAINST ISCHEMIC MYOCARDIAL DAMAGE Institute of Materia, Chinese Academy of Medical Sciences (CN) 2005-06-15 — — EP disclosed
EP-0154851-B1 BENZISOSELENAZOLETHIONES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PRODUCTS CONTAINING THESE COMPOUNDS A. Nattermann & Cie. GmbH (DE) 1989-08-02 — — EP disclosed
EP-0100899-B1 BENZISOSELENAZOLONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM A. Nattermann & Cie. GmbH (DE) 1988-06-15 — — EP disclosed
US-4711961-A Benzisoselenazolethiones and process for the treatment of various diseases in humans A. NATTERMANN & CIE GMBH (DE) 1987-12-08 — — US disclosed
US-4550168-A Benzisoselenazolones and a process for the treatment of inflammatory diseases A. NATTERMANN & CIE GMBH (DE) 1985-10-29 — — US disclosed
EP-0154851-A1 Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds A. Nattermann & Cie. GmbH (DE) 1985-09-18 — — EP disclosed
EP-0100899-A2 Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them A. Nattermann & Cie. GmbH (DE) 1984-02-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135569-A1 Use of benzisoselenazolone compounds against ischemic myocardial damage TNNI3, TNNT2, MYLK2 L3MBTL1 3124/4885LMNA 2539/4885MAPT 4712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback